Tesamorelin + CJC-1295 + Ipamorelin
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
This blend combines three peptides used to stimulate the body’s own growth-hormone (GH) output. Two of them — tesamorelin and CJC-1295 (Modified GRF 1-29) — are analogs of growth-hormone-releasing hormone (GHRH). The third, ipamorelin, is a selective secretagogue that works through a separate receptor. It is usually supplied as a single lyophilized vial.
Tesamorelin is the most clinically studied component and is FDA-approved as a standalone drug (Egrifta) for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. CJC-1295 and ipamorelin, by contrast, have limited human data and are sold for research use only.
The combination itself has not been formally studied as a fixed product. What is known comes from research on the individual compounds, so claims about the blend are best treated as emerging and extrapolated rather than established.
How it works
The two GHRH analogs bind the GHRH receptor on the pituitary to prompt GH release, while ipamorelin acts on the ghrelin receptor (GHS-R1a). Because these are distinct pathways, the compounds are commonly described as complementary — the pairing is thought to encourage a stronger, more sustained pulse of GH than either mechanism alone. Downstream, GH stimulates the liver to produce IGF-I, the mediator of many of GH’s effects.
In healthy adults, CJC-1295 has been shown to raise GH and IGF-I for several days while preserving the natural pulsatile pattern of secretion, and tesamorelin has been studied for its effect on reducing visceral (deep abdominal) fat. Ipamorelin was characterized as the first secretagogue selective for GH release. How these effects combine in a single blend has not been directly measured.
Reported benefits
- Support for lean body composition and recovery (extrapolated from GH/IGF-I effects)
- Reduction of visceral abdominal fat (studied for tesamorelin specifically)
- Increased growth-hormone and IGF-I output (studied for the individual compounds)
- A secretagogue profile that reportedly spares cortisol and prolactin (ipamorelin data)
These are reported or studied effects of the individual compounds, not guaranteed outcomes of the blend.
Considerations & side effects
Reported side effects across these compounds include injection-site reactions, water retention, joint or muscle aches, tingling or numbness, and headache. Because GHRH analogs can raise IGF-I and affect glucose handling, tesamorelin’s clinical trials noted increases in blood sugar and diabetes risk in some participants; benefits also tended to reverse when treatment stopped.
The fixed three-compound blend has not been evaluated for safety as a combined product, and long-term data on CJC-1295 and ipamorelin in humans is limited. Purity in the research-chemical market varies widely. This is educational information only and not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is the tesamorelin + CJC-1295 + ipamorelin blend?
It's a combination product that pairs two growth-hormone-releasing hormone (GHRH) analogs — tesamorelin and CJC-1295 (Mod GRF 1-29) — with ipamorelin, a selective ghrelin-receptor agonist. It is typically sold as a single lyophilized vial and studied for growth-hormone support and body-composition goals.
Why combine three compounds?
The idea behind the stack is complementary mechanisms: the GHRH analogs and the ghrelin-mimetic ipamorelin act on different receptors, so combining them is commonly reported to amplify pulsatile growth-hormone release more than any single agent alone. This rationale is largely theoretical and extrapolated from the individual compounds rather than tested as a blend.
Is this blend FDA-approved?
No. The three-compound blend is not approved by any regulator and is sold for research purposes only. Tesamorelin on its own is FDA-approved as Egrifta for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, but CJC-1295 and ipamorelin are not approved for human therapeutic use.
What is ipamorelin's role in the stack?
Ipamorelin is a selective growth-hormone secretagogue that acts on the ghrelin receptor. In its foundational research it was notable for releasing growth hormone without meaningfully raising cortisol or prolactin, which is why it is often chosen as the secretagogue component of GH blends.
References
- Falutz J, et al. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. ↗
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ↗
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. ↗
Related compounds
Premium growth hormone secretagogue blend combining Tesamorelin and Ipamorelin. Enhances GH release with visceral fat reduction benefits. Sold as a single pre-mixed vial.
Triple GH secretagogue blend combining CJC-1295 (no DAC / Mod GRF 1-29) with two ghrelin mimetics, ipamorelin and GHRP-2, for amplified synergistic GH release. Sold as a single 9mg lyophilized vial.
Pre-mixed blend of CJC-1295 (no DAC) and Ipamorelin for synergistic growth hormone release. Classic GH secretagogue combination sold as a single vial.